HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sildenafil, Tadalafil Among Big Hitters On Upcoming German Switch Committee Agenda

Executive Summary

Possible OTC switches of erectile dysfunction drugs sildenafil and tadalafil, as well as azelastine and fluticasone propionate combination nasal sprays and migraine drug rizatriptan, are on a packed agenda for the next meeting of the German Expert Committee on Prescription.

You may also be interested in...

German Switch Committee Rejects Sildenafil And Tadalafil, Ball Now In Ministry’s Court

Germany’s Expert Committee on Prescription has gone against the wishes of the country's health ministry in rejecting Rx-to-OTC switch applications for sildenafil and tadalafil. The BMG could, in theory, ignore the SVA’s recommendation, however, such a move would be unprecedented. 

ED Indication Reaches US OTC Market With FDA Approval Of UK Firm Futura’s Eroxon Gel

Approved through De Novo regulatory pathway used to classify novel medical devices for which there is no legally marketed predicate product, Eroxon, packaged in single-use tubes, gives Futura first entry to US market for OTC therapeutic products approved with ED indication.

Sanofi Launches OTC Cialis In UK

Men in the UK can now access tadalafil without a prescription with the launch of Sanofi's Cialis Together in Boots pharmacies.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts